Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | NQO2 | P16083 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 5/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582475 | 0.86 | CYP19A1 (0.33) | THRBCYP19A1NQO2BRD4HTT | |
| SCHEMBL21820278 | 0.83 | HSD17B3 (0.38) | MAPTTHRBCYP19A1NQO2SMN1; SMN2 | |
| SCHEMBL21820274 | 0.79 | NQO2 (0.51) | CYP19A1NQO2HSD17B10 | |
| SCHEMBL30236737 | 0.78 | RXFP1 (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL21820211 | 0.78 | RXFP1 (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL21820310 | 0.77 | EPRS1 (0.39) | MAPTCYP19A1NQO2BRD4HTT | |
| SCHEMBL25015193 | 0.75 | MPO (0.33) | MAPTTHRBPOLBBRD4AKT1 | |
| SCHEMBL21820206 | 0.74 | PKM (0.45) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL17509875 | 0.72 | BRD4 (0.37) | MAPTTHRBNQO2POLBBRD4 | |
| SCHEMBL18056961 | 0.72 | EGLN1 (0.44) | MAPTTHRBNQO2BRD4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527093-B | Antibacterial heterocyclic compounds and synthesis thereof | 巴格沃克斯研究有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-110382505-B | Heterocyclic compounds useful as antibacterial agents and process for producing the same | 巴格沃克斯研究有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | Bugworks Research, Inc. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | Bugworks Research, Inc. | 2021-03-11 | — | — | US | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-111527093-A | Antibacterial heterocyclic compounds and synthesis thereof | 巴格沃克斯研究有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | UROD, ALPI, HLA-A | MAPT 13/4885THRB 2551/4885CYP19A1 1736/4885 |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | HLA-B, BAX, REN | MAPT 6/4885THRB 1234/4885CYP19A1 1627/4885 |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | HLA-B, BAX, REN | MAPT 6/4885THRB 1234/4885CYP19A1 1627/4885 |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | UROD, ALPI, HLA-A | MAPT 13/4885THRB 2551/4885CYP19A1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.